Find the right fit for you - faster
Get tailored insights about working at Blue Earth Diagnostics in one quick step.
Blue Earth Diagnostics Snapshot
2 OfficesLocations
Transform the clinical management of patients with cancer by developing and delivering innovative molecular imaging technologies to address unmet clinical needs, and reliably inform diagnosis and treatment decisions
Blue Earth Diagnostics is an established molecular imaging company focused on providing innovative, well-differentiated diagnostics solutions, informing patient management, and driving future therapies in cancer. Formed in 2014, Blue Earth Diagnostics’ success is driven by our management expertise and agility, supported by our demonstrated track record of rapid development and commercialization of PET radiopharmaceuticals. Blue Earth Diagnostics’ clinical focus is exclusively in cancer.
Blue Earth Diagnostics is part of the Bracco Group, an international Group headquartered in Milan, Italy and active in the healthcare sector and a leader in diagnostic imaging. It has around 4,000 employees and annual total consolidated revenues of around 2 billion euros, 89% of which are from international sales. In the R&D area, the company invests approximately 10% of reference turnover in the imaging diagnostics and medical devices sectors. The Group’s main products are contrast agents, medical substances used to improve the diagnostic accuracy of biomedical imaging and the care of patients affected by diseases of varying type and severity. Bracco offers an extensive and innovative portfolio of products and solutions for all diagnostic modalities completed by several medical devices and advanced administration systems for contrast imaging products in the fields of cardiology and radiology. The Company operates in over 110 markets globally.
Blue Earth Diagnostics is part of the Bracco Group, an international Group headquartered in Milan, Italy and active in the healthcare sector and a leader in diagnostic imaging. It has around 4,000 employees and annual total consolidated revenues of around 2 billion euros, 89% of which are from international sales. In the R&D area, the company invests approximately 10% of reference turnover in the imaging diagnostics and medical devices sectors. The Group’s main products are contrast agents, medical substances used to improve the diagnostic accuracy of biomedical imaging and the care of patients affected by diseases of varying type and severity. Bracco offers an extensive and innovative portfolio of products and solutions for all diagnostic modalities completed by several medical devices and advanced administration systems for contrast imaging products in the fields of cardiology and radiology. The Company operates in over 110 markets globally.
